OPEN END TURBO LONG - ORION B | Market Closed - Börse Stuttgart 17:27:12 14/06/2024 BST | ||
| 0.239 EUR | +17.16% |
|
| Current month | -4.02% | ||
| 1 month | -8.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ORION OYJ
Latest news about ORION OYJ
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 0.239 | +17.16% |
| 13/06/24 | 0.204 | -8.52% |
| 12/06/24 | 0.223 | +5.19% |
| 11/06/24 | 0.212 | -33.75% |
| 10/06/24 | 0.32 | -13.51% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 05:27 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ORION OYJ |
| Issuer | Morgan Stanley |
| WKN | MG3CMS |
| ISIN | DE000MG3CMS4 |
| Date issued | 30/04/2024 |
| Strike | 35.34 € |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.39 € |
|---|---|
| Lowest since issue | 0.079 € |
Company Profile
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
-
Consensus: Orion Oyj
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
37.58
EUR
Average target price
38.2
EUR
Spread / Average Target
+1.65%
- Stock Market
- Certificates
- Certificat